Capitainer has closed a share issue to capitalize on growing interest in home-sampling with its new qDBS dried blood spot testing system.
The investment round, led by Sciety, brought in both existing and new industry specialist investors and several board members and the CEO.
“Once again we are delighted to have secured such strong support from experienced medtech and diagnostics industry investors. COVID-19 presented us with an unexpected obstacle, but also a welcomed opportunity to prove the utility of our products. This success has generated unprecedented interest worldwide and the new funding will enable us to accelerate both our product development and commercialisation efforts,” says Ernst Westman, Capitainer Chairman.
“Our home-sampling products have generated interest across the whole spectrum of diagnostic testing. From drugs of abuse to metabolic disorders, we are being contacted by leading specialists in Europe and the US interested in exploring different applications for qDBS. However, this is only half the story, as we will also use this new funding to accelerate our product development to broaden our product platform to include plasma and urine sample collection,” says Christopher Aulin, CEO, Capitainer.